Skip to Content

Clinical Trials Detail

AXIS

Fibroblasts and Mononuclear Fibrogenic Cells Drive Right Ventricular Pulmonary Arterial Uncoupling in Pulmonary Arterial Hypertension

Objective

Project Description

This study involves a multidisciplinary approach with Principal Investigators that have expertise in clinical pulmonary hypertension, in molecular cardiology, and in cell and molecular biology of fibroblasts and circulating mononuclear cells.

Collectively, work by this interdisciplinary group will provide insight into abnormalities of RV-pulmonary arterial interactions in the setting of severe pulmonary hypertension and will lay the groundwork for potential new therapies.

All Other Trials

  • Heart & Circulation
  • Lungs & Respiratory
Contact
Cheri Abbott, RN, CCRP at 303-724-7466
or cheryl.abbott@ucdenver.edu
Eligibility and Other Participant Information

Inclusion Criteria

  • Only subjects that have Idiopathic PH, scleroderma with PH, scleroderma with no PH or have a Patent foramen Ovale with be considered for this study
  • Subjects must be having a right heart cath as part of their clinical workup
  • Subject must be at least 18 years of age
  • Must be able to give informed consent

 

Exclusion Criteria

  • Subjects cannot be immunodeficient
  • Subjects cannot be taking an immunosuppressive agent
  • Subjects cannot have coincident cardiac or pulmonary disease resulting in pulmonary hypertension (WHO categories 2-5)
  • BMI cannot be >35

Location

  • University of Colorado Hospital (UCH)
    12605 E. 16th Ave.
    Aurora, CO 80045